White Paper on In Vitro Diagnostics - Belgium: R&D hotspot

May 31, 2016 News BioVox

The BioVox Diagnostics White Paper presents a privileged insight into successful Belgian diagnostics companies. Download it for free!

Six Belgian IVD experts discuss the challenges and opportunities of in vitro diagnostics. Belgium is an R&D hotspot but commercialization faces several challenges.

Why do VCs shy away from IVD investments? What are the key components of a successful IVD business model? How to patent (or not) diagnostics?

BioVox takes a closer look at Belgian IVD companies successfully balancing innovation and market viability.

The editorial features key opinion leaders in the IVD field:

  • Werner Verbiest (Janssen Diagnostics)
  • Geert Maertens (Biocartis)
  • Luc Segers (Multiplicom)
  • Paul Appermont (ADx Neurosciences)

The report also presents an overview of the Belgian diagnostic industry and academia. 

The BioVox diagnostics white paper is distributed worldwide by BioCentury and the BioVox diagnostics contact database.

BioVox’ next white paper will be on immunotherapy. We would love to include your company and highlight your innovations!
Interested? Contact us at news@biovox.be

Avatar photo

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts